After initially moving away from chemotherapy to focus on more selective targeted therapies, the proverbial pendulum possibly swung too far as resistance to these agents is being recognized and grappled with. The field of targeted therapies in cancer is still relatively young and many questions remain unanswered. Due to the complexity of cancer, effective treatment options in the future will likely require mixing and matching these approaches in different cancer types and different disease stages.
#AZADA RASH HOW TO#
Understanding how to efficiently target cancer cells and overcome resistance to prior lines of therapy became imperative to the success of cancer treatment. Combinations of single kinase inhibitors or alternately multikinase inhibitor drugs could be used to achieve this goal.
However, combinations that target complimentary pathways or potential escape mechanisms appear to be more effective than sequential therapy. Since resistance can be due to several unique mechanisms, there is no one-size-fits-all solution to this problem. Drug resistance can either be de novo or acquired after months or years of drug exposure. Unfortunately, for many patients, resistance to targeted therapies, such as kinase inhibitors, ultimately develops and can necessitate multiple lines of treatment.
Through competitive and noncompetitive inhibition of these kinases, and therefore the pathways they activate, cancers can be slowed or completely eradicated, leading to partial or complete remissions for many cancer types. Chief among targeted therapies is small molecule kinase inhibitors targeting key oncogenic signaling proteins. Development of targeted therapies in recent years revealed several nonchemotherapeutic options for patients.
0 kommentar(er)
